甲状腺分化评分与乳头状甲状腺癌生存结局的关联
研究利用TCGA甲状腺癌队列(N=372)和MDACC队列(N=111)分析甲状腺分化评分(TDS)与乳头状甲状腺癌生存结局的关联。结果显示高TDS与更长的无进展间期相关,仅在MDACC队列校正总分期后仍显著(aHR 0.67,95%CI 0.52-0.85),在BRAFV600E突变肿瘤中关联最一致。
要点
- 在两个队列中,TDS均与诊断时肿瘤分期、淋巴结分期及肿瘤驱动突变状态相关。
- 校正总分期后,TDS仅MDACC队列仍与无进展间期显著相关(aHR 0.67,95%CI 0.52-0.85)。
- BRAFV600E突变肿瘤中,较高TDS与更长无进展间期关联最一致(MDACC:aHR 0.59,95%CI 0.42-0.82)。
核心结论
- TDS可量化乳头状甲状腺癌的分化状态谱,可能作为潜在的预后生物标志物,在BRAFV600E突变肿瘤中最有前景。
研究设计与样本
- 研究使用两个独立的乳头状甲状腺癌患者队列:癌症基因组图谱(TCGA)甲状腺癌研究(N=372)和MD安德森癌症中心(MDACC)队列(N=111)。
- 主要生存结局为无进展间期(PFI),同时探索总生存(OS)的关联。
- 采用Kaplan-Meier法和Cox比例风险模型进行生存分析。
主要发现
- 在两个队列中,TDS均与诊断时肿瘤分期、淋巴结分期及肿瘤驱动突变状态相关。
- 单因素分析中,高TDS与更长的无进展间期相关(跨队列)。
- 校正总分期后,TDS仅在MDACC队列仍与无进展间期显著相关(校正风险比[aHR] 0.67,95%CI 0.52-0.85)。
- 按肿瘤驱动突变状态分层分析,校正总分期后,较高TDS与更长无进展间期的关联在MDACC队列的BRAFV600E突变肿瘤中最一致(TCGA:aHR 0.60,95%CI 0.33-1.07;MDACC:aHR 0.59,95%CI 0.42-0.82)。
- 在MDACC总体队列中,TDS升高与更长总生存相关(aHR=0.78,95%CI 0.63-0.96),中位随访时间为12.9年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid differentiation score (TDS), calculated based on mRNA expression levels of 16 genes controlling thyroid metabolism and function, has been proposed as a measure to quantify differentiation in papillary thyroid carcinoma (PTC). OBJECTIVE: The objective of this study is to determine whether TDS is associated with survival outcomes across patient cohorts. METHODS: Two independent cohorts of patients with PTC were used: (1) The Cancer Genome Atlas (TCGA) thyroid cancer study (N = 372), (2) MD Anderson Cancer Center (MDACC) cohort (N = 111). The primary survival outcome of interest was progression-free interval (PFI). Association with overall survival (OS) was also explored. The Kaplan-Meier method and Cox proportional hazards models were used for survival analyses. RESULTS: In both cohorts, TDS was associated with tumor and nodal stage at diagnosis as well as tumor driver mutation status. High TDS was associated with longer PFI on univariable analyses across cohorts. After adjusting for overall stage, TDS remained significantly associated with PFI in the MDACC cohort only (adjusted hazard ratio [aHR] 0.67, 95% CI 0.52-0.85). In subgroup analyses stratified by tumor driver mutation status, higher TDS was most consistently associated with longer PFI in BRAFV600E-mutated tumors in the MDACC cohort after adjusting for overall stage (TCGA: aHR 0.60, 95% CI 0.33-1.07; MDACC: aHR 0.59, 95% CI 0.42-0.82). For OS, increasing TDS was associated with longer OS in the overall MDACC cohort (aHR = 0.78, 95% CI 0.63-0.96), where the median duration of follow-up was 12.9 years. CONCLUSION: TDS quantifies the spectrum of differentiation status in PTC and may serve as a potential prognostic biomarker in PTC, mostly promisingly in BRAFV600E-mutated tumors.
引用
- Wang JR, Zafereo ME, Cabanillas ME, et al. The Association Between Thyroid Differentiation Score and Survival Outcomes in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2025. PMID: 39087944. doi:10.1210/clinem/dgae532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。